SCL Science resolves to merge with SCL Healthcare… integrating data-driven precision medicine
Predicted impact: Medium
Merger with SCL Healthcare already flagged as 'Merger decision' recently; likely a small affiliate deal, size unknown.
SCL ScienceSCL사이언스
246960 · KOSDAQ · ₩246960 · SCL사이언스
₩2,140▼ ₩70 (3.17%)End-of-day · Oct 30, 2026 · End-of-day prices.
Price · 1Y −12.47%
- Market cap
- ₩74B
- Enterprise value
- ₩94B
- P/E
- —
- P/B
- 3.1×
- Dividend yield
- 0.0%
- ROE
- −14.0%
- Net margin
- −11.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−27.2% from the high
₩1,389Today: ₩2,020 – ₩2,365₩2,940
Returns
- 1W−7.0%
- 1M−18.3%
- 3M+32.8%
- 6M+4.9%
- YTD−7.0%
- 1Y−12.5%
- Volume today
- 179,698
- 1.2× the 20-day average
- Traded today
- ₩373M
- Listed shares
- 34,793,688
- EPS (12 months)
- −₩97
- Earnings yield −4.5%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 43 of 100 (50 is a normal day for this stock).
- SentimentMixedNews: The merger decision is a neutral corporate event with no stated financial impact in the sources. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-23.4% over the last month; the price is below its 20-day average.
- News impactSome4 news items and filings in two weeks; 0 rated high impact, 2 medium.
Signals describe activity, not recommendations. Not financial advice.
SCL Science stock overview
SCL Science (SCL사이언스, KRX: 246960) is listed on KOSDAQ, in the Biotech & Pharma sector. Korean company developing protein-based platform technologies, with a medical sealant business whose InnoSEAL hemostatic products (for vascular procedures and abdominal surgery) are marketed and held approvals, including InTro and InnoSEAL Plus DL. Its shares closed at ₩2,140 on Oct 30, 2026, down 3.17% on the day, giving it a market value of ₩74B.
Key facts
- Market cap
- ₩74B
- Sector
- Biotech & Pharma
- Latest price change
- −3.17%
- As of
- Oct 30, 2026
- Main business
- Korean company developing protein-based platform technologies, with a medical sealant business whose InnoSEAL hemostatic products (for vascular procedures and abdominal surgery) are marketed and held approvals, including InTro and InnoSEAL Plus DL.
Quick answers about SCL Science
- What does SCL Science do?
- Korean company developing protein-based platform technologies, with a medical sealant business whose InnoSEAL hemostatic products (for vascular procedures and abdominal surgery) are marketed and held approvals, including InTro and InnoSEAL Plus DL. It also runs a bio logistics business providing temperature-controlled cold chain transport of human-derived materials, biologics, pharmaceuticals and medical devices, and a healthcare data platform business offering AI imaging analysis and integrated health checkup management software for medical institutions.
- What is the market cap of SCL Science?
- The market capitalisation of SCL Science was ₩74B at the close on Oct 30, 2026.
- Who are the largest shareholders of SCL Science?
- According to the latest official filings, the largest reported holders are SCL Holdings (49.33%, as of Aug 11, 2025); Daeshin New Technology Investment Partnership No. 15 (7.65%, as of Jan 10, 2025); Kim Kyung-soo (4.85%, as of Aug 18, 2026).
- When is the next earnings report from SCL Science?
- Korean companies rarely announce results dates in advance. Based on when SCL Science filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
Korean company developing protein-based platform technologies, with a medical sealant business whose InnoSEAL hemostatic products (for vascular procedures and abdominal surgery) are marketed and held approvals, including InTro and InnoSEAL Plus DL. It also runs a bio logistics business providing temperature-controlled cold chain transport of human-derived materials, biologics, pharmaceuticals and medical devices, and a healthcare data platform business offering AI imaging analysis and integrated health checkup management software for medical institutions.
Written by AI from the company's latest annual report.
- Korean name
- SCL사이언스
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 이경률, 백세연 (각자대표)
- Founded
- Apr 2010
- Listed
- Feb 2019
- Listed shares
- 34,793,688
- Fiscal year ends
- Month 12
- Website
- www.innotherapy.com
Similar companies
- Samsung Biologics207940 · ₩69T₩1,487,000+8.86%
- Celltrion068270 · ₩44T₩191,600+1.22%
- Alteogen196170 · ₩15T₩211,500−3.86%
- SK biopharmaceuticals326030 · ₩6.1T₩77,700−0.13%
- Yuhan000100 · ₩5.5T₩75,100+0.54%
- HLB028300 · ₩5.3T₩40,000+0.76%
- Hanmi Pharm128940 · ₩5.3T₩415,000+6.82%
- SAM Chun Dang Pharm000250 · ₩4.3T₩182,700−3.13%
Recent news
SCL Science signs MOU with Pakistani local firm to distribute 'InoSeal' hemostatic pad
Predicted impact: Low
Small distribution MOU in Pakistan with no disclosed value, small relative to company size.
SCL Sciences Launches Southeast Asia Push With Vietnam's Hue Central Hospital and Kinoti
Predicted impact: Low
Southeast Asia hospital partnership in Vietnam; small, vague, no size given.
Recent filings
See all- Merger decisionOct 29, 2026
- Exercise of Conversion RightsOct 16, 2026
- Investor relations (IR) eventOct 6, 2026
- Amended: Major sales or supply contractSep 30, 2026
- Amended: Investor relations (IR) eventSep 21, 2026
Titles in Korean until English translations are added.
Also known as: SCL Science / SCL사이언스 / 246960 / KRX:246960
Source: KRX statistical information